The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 347:67-68 July 4, 2002 Number 1
NextNext

Imatinib and Chronic-Phase Leukemias

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Savage, D. G.
-PubMed Citation
To the Editor: Savage and Antman (Feb. 28 issue)1 summarize the pathogenesis of BCR-ABL–positive chronic-phase leukemias that are responsive to imatinib mesylate therapy. The authors point out that the mechanism of the antiproliferative action of imatinib lies in its effective control of BCR-ABL tyrosine kinase activity, thus interfering with the promotion of the phosphorylation of multiple substrates of mitogenic signaling pathways. The precise oncogenic mechanism of BCR-ABL is still unknown.

There are important changes in the metabolic profile of BCR-ABL–positive cells after their reversion as a result of imatinib mesylate treatment. Hematopoietic cells transfected with BCR-ABL express the high-affinity GLUT-1 . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.